These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 36640225)

  • 1. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
    Front Genet; 2022; 13():947551. PubMed ID: 35938003
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Xu C; Chen A; Mao C; Cui B
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    Zhu S; Li H; Fan Y; Tang C
    BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis Combined with lncRNAs Predicts the Prognosis and Immune Microenvironment of Breast Cancer.
    Zhang L; Zhang Y; Bao J; Gao W; Wang D; Pan H
    Comput Math Methods Med; 2022; 2022():5422698. PubMed ID: 36213577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
    Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
    Front Genet; 2023; 14():1096783. PubMed ID: 36911392
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
    Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
    Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.